Tue.Feb 27, 2024

article thumbnail

Perrigo plots hundreds of job cuts as it embarks on restructuring initiative

Fierce Pharma

Over-the-counter self-care specialist Perrigo is poised to leave hundreds of workers by the wayside as it embarks on the next leg of its corporate journey. | As part of a cost-cutting and restructuring initiative dubbed "Project Energize," Perrigo expects to trim roughly 6% of its total staff, the company said in a fourth-quarter earnings release Tuesday.

307
307
article thumbnail

Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations

MedCity News

The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial.

Biopharma 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure

Fierce Pharma

AstraZeneca and FibroGen have finally reached the end of the road for their U.S. collaboration on the oral anemia drug roxadustat. | More than two years after a high-profile FDA rejection, AstraZeneca has backed out of a collaboration with FibroGen for the latter’s oral anemia drug roxadustat in the U.S. Still, AZ left the partners' China pact intact.

FDA 300
article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. Dame June will remain in the position until then to support the new Chief Executive’s transition into the role. Leading the MHRA – a five year journey Professor Graham Cooke, interim chair of the MHRA board, remarked that Dame June’s “leadership of the MHRA over the last five years, particularly during the COVID-19 pand

Safety 111
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

One Up, One Down: Allecra scores FDA nod for antibiotic combo after Venatorx hit with rejection

Fierce Pharma

Over the last few days, as the FDA rejected one antibiotic combination treatment for complicated urinary tract infections (cUTIs), it has approved another. | Over the last few days, as the FDA rejected one antibiotic combination treatment for complicated urinary tract infections (cUTIs), it has approved another. The U.S. regulator has signed off on Allecra Therapeutics’ Exblifep as a treatment for cUTIs, including the severe kidney condition pyelonephritis.

FDA 239
article thumbnail

Amgen opens its most advanced manufacturing facility to date

European Pharmaceutical Review

Amgen has opened a new biomanufacturing plant in Central Ohio, US. It is the company ’s most advanced manufacturing facility to date. The new facility, known as Amgen Ohio, “was designed with the latest innovation and technology to deliver safe, reliable medicines for ‘every patient, every time,'” stated Robert Bradway, Chairman and Chief Executive Officer at Amgen. “As part of Amgen’s global biomanufacturing network, Amgen Ohio will play an important role in helping us

More Trending

article thumbnail

Janux Rides Its TRACTr to Validation in Prostate Cancer and More Solid Tumors

MedCity News

A Janux Therapeutics T cell engager has early clinical data showing improvement in cases of advanced prostate cancer, validating the technology platform that produced the therapy. Janux is now leveraging its soaring stock price to raise $175 million in a stock offering.

Biopharma 107
article thumbnail

BioMarin testing programs for 2 top-selling drugs under scrutiny from DOJ

Fierce Pharma

BioMarin has provided documents to the U.S. | BioMarin has provided documents to the U.S. Department of Justice in response to a subpoena which requested information on the company’s government-sponsored testing programs for enzyme replacement therapies Vimizim and Naglazyme.

article thumbnail

Trademarks on the rise: applications recover in 2023 after a dip in 2022

Clarivate

When global trademark filing activity fell in 2022 , questions rose around what this signified. Would 2023 data show a second year of decline, indicating uncertain economic outlooks? Or would filing activity recover? To answer this question, we dove into curated trademark data from CompuMark to analyze application and filing history. With access to over 147 million trademark records, including application and filing history gathered directly from Patent and Trademark Offices (PTOs) such as the E

article thumbnail

Rising Investment in Patient Support Drives a Greater Biopharma Focus on Measurement

Fierce Pharma

A seismic shift has occurred in the healthcare landscape. | Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. As pharmaceutical companies' channel ever-increasing resources into these transformative initiatives, the need for robust and comprehensive measurement becomes not just an option, but an imperative, in order to validate allocation of resources and effectiveness of the investment.

Biopharma 197
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA says yes to Allecra, no to Venatorx UTI drugs

pharmaphorum

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but turned down a rival product from Venatorx.

FDA 100
article thumbnail

Growth or Profitability: Which One Do Investors Care More About?

MedCity News

In the venture capital community, there’s a bit of a debate about what matters more to digital health investors in today’s fundraising environment — growth or profitability. Cathy Gao, a partner at Sapphire Ventures, thinks VCs are still putting a premium on growth, but she noted that the conversation is very nuanced.

102
102
article thumbnail

Study rings warning bell over cancer therapy access in UK

pharmaphorum

UK cancer survival is lagging 10-15 years behind other countries due to lower rates of chemotherapy and radiotherapy, says UCL study backed by CRUK.

103
103
article thumbnail

Seven Trends to Watch in Healthtech AI

MedCity News

As the role of AI in healthcare settings continues to evolve and generate debate, here are seven things to keep an eye on.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Bristol Myers Squibb acquires RayzeBio for $4.1bn

Pharmaceutical Technology

Bristol Myers Squibb (BMS) has announced the conclusion of its acquisition of RayzeBio, a radiopharmaceutical company, for $4.1bn.

104
104
article thumbnail

UK biotech Curve swings £40.5m in Pfizer-backed round

pharmaphorum

UK biotech Curve Therapeutics raises $51 million in a Pfizer-led Series A that will support its platform for screening drugs within cells.

105
105
article thumbnail

It’s Time to Evolve Beyond FMTs and Advance LBPs

MedCity News

The FMT era has been productive, but now it’s time to rally together as an industry to accelerate next-generation LBP drug discovery, development and FDA approval.

FDA 101
article thumbnail

Minerva slumps as FDA finds fault with schizophrenia filing

pharmaphorum

FDA has turned down Minerva Neurosciences' marketing application for roluperidone as a treatment for the negative symptoms of schizophrenia

FDA 101
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Blackbird Health Secures $17M To Expand Youth Mental Health Model

MedCity News

Blackbird Health’s $17 million Series A funding round was led by Define Ventures and included participation from Frist Cressey Ventures and GreyMatter. In total, the startup has raised nearly $23 million.

96
article thumbnail

Novo Nordisk signs $1.46bn deal to develop molecular glue therapies

Pharmaceutical Technology

Novo Nordisk has partnered with US startup Neomorph to develop multiple molecular glue degraders for cardiometabolic and rare diseases.

98
article thumbnail

Beyond Faith: Can Hospitals Collect When Patients Rely on Sharing Ministries?

MedCity News

There is a ubiquitous lack of understanding and regulation surrounding the HCSM coverage which leaves hospitals stuck with the bill and negatively impacts the bottom line.

article thumbnail

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

PharmaTech

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.

98
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Novo Nordisk joins molecular glue club with Neomorph deal

pharmaphorum

Novo Nordisk has signed a wide-ranging deal with US molecular glue biotech Neomorph that could be worth up to $1.46 billion.

100
100
article thumbnail

Operational risks with gene therapies should improve with time, exec says

Pharmaceutical Technology

Making therapies feasible from biological, regulatory, and commercial standpoints drives scalable genetic medicine.

article thumbnail

Sponge-on-a-string test to benefit NHS patients with oesophageal cancer

PharmaTimes

Eight out of ten patients who took the test were discharged without needing further testing

article thumbnail

EMA Recommends New ALS Treatment

PharmaTech

The agency has recommended granting marketing authorization to ALS treatment, Qalsody (tofersen), for adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

UK and Netherlands researchers call for funding to investigate cancer treatments

PharmaTimes

The white paper outlines three strategic recommendations to support further research

92
article thumbnail

Innovation takes precedence with AI use for techbios in pharma

Pharmaceutical Technology

The industry must utilise AI with the mindset to innovate over the desire to slash drug costs and reduce time to commercialisation.

Pharma 64
article thumbnail

Six ways AI can help providers drive transformation in healthcare

Clarify Health

In the United States, an aging population and the rising prevalence of chronic disease highlight the limitations of most healthcare systems, putting increased pressure on providers. Artificial intelligence (AI) can be a potent tool providers and healthcare leaders can use to help identify inefficiencies and reduce costs without compromising quality.

article thumbnail

From Medical Sales To Medical Entrepreneurship With Tim Lew

Evolve Your Success

Some of us thrive with more freedom, and so often, that means embracing entrepreneurship in this space. If you are looking for inspiration to go from medical sales to medical entrepreneurship, this is the episode for you. Samuel Adeyinka introduces us to Tim Lew , who takes us on a journey through his unique academic background to a successful career in medical device sales and distributorship.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A